INITIATIVE FOR MEDICINES, ACCESS & KNOWLEDGE
Sofosbuvir is a pipeline hepatitis C (HCV) drug that has been recommended for treatment by the US FDA and EMA. HCV is a significant public health issue for low- and middle-income countries, that are home to 90% of the 185 million people who are infected with HCV. Although HCV is curable, high drug prices make treatment inaccessible, leaving people at risk for liver cancer or liver failure.
I-MAK filed an opposition against Gilead/Pharmasset's patent applications because we believe that the technologies comprising these patent applications are known and therefore undeserving of a patent grant. We also believe that it is now time that People Living with HCV obtain affordable access to the drugs they need.
Legal Documents for Opposition to Sofosbuvir (India)
Except for publications commissioned or published by third parties all content on this site is licensed under a Creative Commons Attribution 3.0 License